Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unm...
Task 3.3
Development of a PET tracer against S100A9...
Description
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- Roche (Switzerland)Switzerlandhttp://www.roche.ch/en/index.htm
- Pfizer (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.pfizer.co.uk/
- Takeda (United Kingdom)United Kingdom of Great Britain and Northern Ireland (the)http://www.takedacam.com/
- University of Münster (UM)Germanyhttps://www.uni-muenster.de
Additional organisations
- Antaros Medical (Sweden)Swedenhttps://antarosmedical.com/
- Bayer (Germany)Germanyhttp://www.gesundheit.bayer.de/de/index.php
- Vall d'Hebron Institut de Recerca (VHIR; VHIR-CERCA)Spainhttps://vhir.vallhebron.com
- Vall d'Hebron Institute of Oncology (VHIO; VHIO-CERCA)Spainhttps://www.vhio.net
Data originator, Data holder, Data provider
- ImaginAb (United States)United States of America (the)https://www.imaginab.com/
- Janssen (Belgium)Belgiumhttps://www.janssen.com/belgium/
- LygatureNetherlands (the)https://www.lygature.org/
- Amsterdam UMC Location Vrije Universiteit Amsterdam (VUMC)Netherlands (the)https://vumc.nl
- University of CambridgeUnited Kingdom of Great Britain and Northern Ireland (the)https://www.cam.ac.uk
Networks
Part of networks...